Aptamer Therapeutics Consulting Group
Aptamer Therapeutics Consulting Group (ATCG) harnesses the Raptamer™ technology to develop novel therapeutic strategies for a variety of diseases such as infectious diseases, autoimmune diseases and cancer. Raptamers™ combine therapeutic advantages of monoclonal antibodies and small molecule drugs, providing high binding affinity and specificity to specific targets while requiring short generation time and low cost for up-scale production. ATCG collaborates with renowned scientists from top-tier research institutes including MDACC, BCM, UCSC, TAMU and UTSW to bring aptamer-based therapeutics from bench to bedside.
Contact us for more information.